A Pragmatic INitiative for LDL-C Management by a CLinical Pharmacist-Led Team Among Atherosclerotic CardiovascUlar DisEase Patients
A Pragmatic INitiative for LDL-C Management by a CLinical Pharmacist-Led Team Among Atherosclerotic CardiovascUlar DisEase Patients (The INCLUDE Trial)
Intermountain Health Care, Inc.
400 participants
Jan 30, 2025
INTERVENTIONAL
Conditions
Summary
Patients who had an ASCVD event at an Intermountain hospital will be screened for eligibility to be randomized. Subjects who meet eligibility criteria will be randomized 1:1 to receive targeted care of their LDL-C through a pharmacist-driven management program or not. Patients may opt-out of receiving LDL-C management by the pharmacy team at any time. The purpose of this program is to increase the proportion of patients who achieve guideline-based recommendations of LDL-C levels of \<70 mg/dL by increasing statin and/or LLT adherence and LDL-C testing. Data collection as part of the study will continue until the last person randomized has had 1-year of follow-up.
Eligibility
Inclusion Criteria7
- Male or female >18 years of age
- Receive follow-up care with Intermountain Health
- Value-based patient (as defined in the EDW)
- Documentation of an ASCVD diagnosis, by 1 of the following:
- Coronary artery disease (Primary inpatient CAD diagnosis during index encounter; Primary inpatient MI diagnosis during index encounter; PCI during index encounter; or CABG during index encounter
- Cerebrovascular accident (Primary inpatient ischemic stroke diagnosis during index encounter; Carotid endarterectomy during index encounter; or Carotid stent during index encounter)
- Peripheral arterial disease (Bypass or percutaneous intervention during index encounter)
Exclusion Criteria3
- Patient age <18 years.
- Receipt of or expected receipt of palliative care, expected discharge to hospice, or long-term care facility (i.e., skilled nursing facility).
- Pregnant or lactating women
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Patients will receive targeted care of their LDL-C through a pharmacist-driven management program.
Patient will receive usual care for their LDL-C management.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06571162